BioCryst Pharmaceuticals
BCRX
BCRX
116 hedge funds and large institutions have $443M invested in BioCryst Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 23 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
1% more capital invested
Capital invested by funds: $439M → $443M (+$4.9M)
3% less funds holding
Funds holding: 120 → 116 (-4)
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
Holders
116
Holding in Top 10
3
Calls
$907K
Puts
$577K
Top Buyers
| 1 | +$15.3M | |
| 2 | +$11M | |
| 3 | +$10.8M | |
| 4 |
BlackRock
New York
|
+$4.88M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.58M |
Top Sellers
| 1 | -$7.31M | |
| 2 | -$7.06M | |
| 3 | -$3.36M | |
| 4 |
D.E. Shaw & Co
New York
|
-$2.71M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$2.62M |